Clinical Practice Guidelines Committee

Introduction

Chair: Dr Andy Lewington, andrew.lewington@nhs.net.

The Clinical Practice Guidelines Committee was established by the UK Renal Association (RA) to prepare guidelines for the management of patients with renal disease and help identify the data to be collected by the Renal Registry.

The RA has produced guidance on best practice in the management of patients with kidney disease since 1995. The RA Clinical Practice Guidelines are not funded by any external organisation, commercial company or charity.

In 2013 it was agreed that for appropriate topics The Renal Association would produce joint adult and paediatric guidelines with the British Association for Paediatric Nephrology .

NICE Accreditation

The National Institute for Health and Care Excellence (NICE) has accredited the process used by The Renal Association to produce its Clinical Practice Guidelines. Accreditation is valid for 5 years from 9 November 2010.

Accreditation helps health and social care professionals identify the most robustly produced guidance available, enabling them to deliver high quality care.

More information on accreditation can be viewed at http://www.nice.org.uk/accreditation

 

Clinical Practice Guidelines Committee 2016

Dr. Richard Baker
Dr. Vicky Briggs        
Dr. Clara Day   
Dr. Elizabeth Garthwaite                       
Dr.  Paul Harden                              
Dr. Suren Kanagasundaram
Dr. Mick Kumwenda
Dr. Andy Lewington (Chair)   
Dr. Elizabeth Lindley    
Dr. Simon Lines
Dr. Mark MacGregor 
Dr. Patrick Mark        
Dr. Shona Methven
Dr. Ashraf Mikhail                           
Dr.  Sandip Mitra                 
Dr. Andrew Mooney
Dr. Marlies Ostermann
Dr. Mike Robson
Dr. Ed Sharples
Dr. Simon Steddon  
Ms. Elizabeth Southcott   
Dr.Graham Warwick
Dr. Martin Wilkie                             
Dr. Graham Woodrow
Dr.Mark Wright 

Current Edition of the Clinical Practice Guidelines

Guidelines Date Review due
Acute Kidney Injury - Dr Andrew Lewington & DrSuren Kanagasundaram 08/03/11 2015
Anaemia in CKD - Dr Ashraf Mikhail, Dr Rajesh Shrivastava & Dr Donald Richardson 15/11/10 2015 
Assessment of the Potential Kidney Transplant Recipient - Dr Chris Dudley & Dr Paul Harden 12/01/11  2015 
Blood-borne viruses - Dr Colin Geddes, Dr Elizabeth Lindley & Dr Neill Duncan 14/07/09 2014
Cardiovascular disease in CKD - Dr Stephen Holt & Dr David Goldsmith 06/08/10  2015 
CKD-Mineral and Bone Disorders (CKD-MBD) - Dr Simon Steddon & Dr Edward Sharples
01/03/15 2020
Detection, Monitoring and Care of Patients with CKD - Dr Mark S. MacGregor & Dr Maarten W. Taal 28/02/11 2015
Haemodialysis - Dr Robert Mactier, Dr Nic Hoenich & Dr Cormac Breen 01/12/09 2012 
Nutrition in CKD - Dr Mark Wright & Dr Colin Jones 25/06/10  2015 
Peritoneal access - Dr Martin Wilkie, Dr Sarah Jenkins & Dr Badi Shrestha 22/09/09  2014 
Peritoneal dialysis - Dr Graham Woodrow & Prof Simon Davies 30/07/10 2015 
Planning, initiation & withdrawal of Renal Replacement Therapy - Dr Graham Warwick & Dr Andrew Mooney 01/02/14 2019 
Post-operative Care of the Kidney Transplant Recipient - Dr R Baker, Professor A Jardine & Dr Peter Andrews 05/02/11 2015 
Vascular Access For Haemodialysis - Dr Mick Kumwenda, Dr Sandip Mitra & Dr Claire Reid 31/3/2015 2020

 

Recent Activity

Tolvaptan for treating autosomal dominant polycystic kidney disease

In October 2015, NICE recommended that Tolvaptan (JINARC®) therapy should be made available for selected patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in England and Wales In January 2016, the Scottish Medicines Consortium (SMC) also approved Tolvaptan for use in Scotland. Currently Tolvaptan is being used in Canada, Japan, Korea and Switzerland for ADPKD and has been approved for use in Europe by the European Medicines Agency (EMA). 

NICE recommended that patients with ADPKD who may be eligible for treatment must have Stage 2 or 3 chronic kidney disease (CKD) and ‘evidence of rapidly progressing disease’. SMC have approved its use for Stages 1-3 CKD, similar to that recommended by the EMA. The definition and evaluation of ‘rapid progression’ are however not established and have not been stipulated by NICE, SMC or the EMA.  The main purpose of this commentary is to address the issue of how to identify patients with evidence of or who are at risk of rapid disease progression.

The draft guideline will is available to you for consultation and feedback over the next 3 months; please send your  comments  to Professor Ong at a.ong@sheffield.ac.uk

Please click here to view the draft guideline


Guidelines to Review- Guideline on water treatment systems, dialysis water and 
dialysis fluid quality for haemodialysis and related therapies

The primary aim of this guideline is to assist the entire multidisciplinary team involved in the provision of water for haemodialysis by providing a single, user friendly document in ensuring  the delivery of fit for purpose dialysis water and dialysis fluid.

The second aim of this guideline is to reduce adverse events in the planning, installation, operation and maintenance of water treatment facilities in the UK that may cause risks to patients.

The document which has been peer reviewed and approved by the Association of Renal Technologists and Renal Association. It is NOT intended to replace the National standards and the interpretive guidance MUST be read in conjunction with such National Standards.

The draft guideline will be posted for 4 weeks. Please send all feedback to nahoenich@gmail.com

Click here to view the draft guideline.

 

© Renal Association 2013
All rights reserved. Use of this website constitutes acceptance of the Privacy Policy and Terms and Conditions.

Design and Development  by MCI
Community 
Twitter
Contact us
The Renal Association
Durford Mill
Petersfield
Hampshire
GU31 5AZ
UK
Tel: 01730 715 215
Fax: 01730 715 291